Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 4/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19603733 | 0.82 | MGLL (0.37) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL1535503 | 0.80 | GAA (0.42) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL2756780 | 0.78 | MGLL (0.34) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL3470187 | 0.77 | MGLL (0.37) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL12414217 | 0.77 | MGLL (0.48) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL1535492 | 0.77 | MGLL (0.44) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL1535480 | 0.77 | MGLL (0.33) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL17104494 | 0.76 | MGLL (0.31) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL24574686 | 0.76 | ALDH1A1 (0.36) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL3482787 | 0.75 | MGLL (0.47) | MGLLGMNNALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054332-A1 | THOMBOPOIETIN PEPTIDE CONJUGATES | CONJUCHEM BIOTECHNOLOGIES, INC. (CA) | 2009-02-26 | — | — | US | claimed |
| US-20240199695-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2024-06-20 | — | — | US | disclosed |
| WO-2024103161-A1 | DRUG CONJUGATE COMPOUNDS FOR STIMULATING THE ANTITUMOR IMMUNE RESPONSE | THERATECHNOLOGIES INC. (CA) | 2024-05-23 | — | — | WO | disclosed |
| US-20240156971-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | TRANSFERT PLUS, SOCIÉTÉ EN COMMANDITE (CA) | 2024-05-16 | — | — | US | disclosed |
| EP-4297795-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | Transfert Plus, Société en Commandite (CA) | 2024-01-03 | — | — | EP | disclosed |
| CN-117320756-A | Methods for targeting cancer stem cells and conjugated compounds that bind sortilin | 特拉斯福特普拉斯公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11780882-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | TRANSFERT PLUS, S.E.C. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2023-02-02 | — | — | US | disclosed |
| EP-4069309-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2022-10-12 | — | — | EP | disclosed |
| US-20220000971-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | TRANSFERT PLUS, S.E.C. (CA) | 2022-01-06 | — | — | US | disclosed |
| US-20170326233-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC (CA) | 2017-11-16 | — | — | US | disclosed |
| US-20170281787-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC (CA) | 2017-10-05 | — | — | US | disclosed |
| EP-3218414-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | Angiochem Inc. (CA) | 2017-09-20 | — | — | EP | disclosed |
| WO-2017088058-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016074093-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC. (CA) | 2016-05-19 | — | — | WO | disclosed |
| US-20160106856-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC. (CA) | 2016-04-21 | — | — | US | disclosed |
| EP-2885321-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | Angiochem Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026286-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC. (CA) | 2014-02-20 | — | — | WO | disclosed |
| US-20090054332-A1 | THOMBOPOIETIN PEPTIDE CONJUGATES | CONJUCHEM BIOTECHNOLOGIES, INC. (CA) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157824-A2 | THROMBOPOIETIN PEPTIDE CONJUGATES | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | SORT1, NGLY1, SNX9 | GABBR2 4098/4885GABBR1 4501/4885MGLL 2883/4885 |
| US-20240199695-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | NGLY1, VIP, NPY1R | GABBR2 3013/4885GABBR1 4037/4885MGLL 3940/4885 |
| US-20170326233-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | VIP, KLKB1, SERPINA3 | GABBR2 3296/4885GABBR1 3167/4885MGLL 2577/4885 |
| US-20240156971-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | SORT1, CD44, SCARB1 | GABBR2 4047/4885GABBR1 4288/4885MGLL 3137/4885 |
| US-20170281787-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | VIP, KLKB1, ADAM17 | GABBR2 3562/4885GABBR1 3516/4885MGLL 2906/4885 |
| US-20220000971-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | SORT1, FLT1, FLT4 | GABBR2 4029/4885GABBR1 4433/4885MGLL 2896/4885 |
| US-11780882-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | NGLY1, VIP, NPY1R | GABBR2 3099/4885GABBR1 4053/4885MGLL 4116/4885 |
| US-20090054332-A1 | THOMBOPOIETIN PEPTIDE CONJUGATES | TEK, MPL, PTMS | GABBR2 4283/4885GABBR1 4357/4885MGLL 4269/4885 |
| US-20160106856-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | VIP, KLKB1, ADAM17 | GABBR2 3562/4885GABBR1 3516/4885MGLL 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.